Sol-Gel Technologies Ltd. SLGL 深 滬
等待開盤 07-23 09:30:00 美东时间
84.30
-5.440
-6.06%
華盛通- 最 高93.74
- 今 開91.70
- 成交量 4.33万股
- 最 低 83.62
- 昨 收 89.74
- 總市值 2.76亿
- 52周最高 97.97
- 市盈率 靜 --
- 換手率 1.33%
- 52周最低 12.50
- 委 比 -8.26%
- 總股本 326.90万
- 歷史最高 210.00
- 量 比 0.70
- 振 幅 11.28%
- 歷史最低 3.34
- 每 手 1
- 風險率 23.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $110 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $110 price target.
07-20 19:22
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
Mizuho Initiates Coverage On Sol-Gel Technologies with Outperform Rating, Announces Price Target of $285
Mizuho analyst Uy Ear initiates coverage on Sol-Gel Technologies (NASDAQ:SLGL) with a Outperform rating and announces Price Target of $285.
06-24 18:07
Sol-Gel Technologies Q1 EPS $(1.31) Beats $(1.84) Estimate, Sales $108.000K Miss $900.000K Estimate
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.84) by 28.8 percent. This is a 59.06 percent increase over losses of $(3.20) per share
05-28 20:38
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) shares increased by 59.4% to $2.28 during T...
03-25 01:05
BRIEF-Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering
BRIEF-Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering March 23 (Reuters) - Sol Gel Technologies Ltd SLGL.O : SOL-GEL TECHNOLOGIES LTD. ANNOUNCES PRICING OF OVERSUBSCRIBED UNDERWRITTEN OFFERING SOL GEL TECHNOLOGIES LTD - SOL-GEL TECHNOLOGIES PRICES 459,112 SHARES A
03-24 09:39
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. announced the pricing of an underwritten offering of 459,112 ordinary shares at $72.00 per share, raising approximately $33.1 million. The funds will support the development of SGT-610, a Phase 3 topical hedgehog inhibitor for Gorlin syndrome, with potential applications in high-frequency basal cell carcinoma. The offering includes participation from notable investors and is expected to close on March 25, 2026. Sol-Gel i...
03-24 01:38
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Sol-Gel Technologies Ltd. filed its annual report on Form 20-F for 2025, available on the SEC website and its investor relations site. The company is advancing rare skin disease therapies, including SGT-610, a Phase 3 topical hedgehog inhibitor for Gorlin syndrome patients, and SGT-210, a topical EGFR inhibitor. Sol-Gel also markets FDA-approved dermatology products TWYNEO® and EPSOLAY®.
03-19 12:53
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Shares of pharmaceutical companies are trading lower amid overall market weakne...
03-06 03:56
